LAVA Therapeutics downgraded by Leerink Partners with a new price target

12/12/24 8:11:38 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Leerink Partners downgraded LAVA Therapeutics from Outperform to Market Perform and set a new price target of $2.00 from $11.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LVTX

Date	Price Target	Rating	Analyst
12/12/2024	$11.00 → $2.00	Outperform → Market Perform	Leerink Partners
12/11/2024		Mkt Outperform → Mkt Perform	JMP Securities
10/25/2022	$9.00	Buy	H.C. Wainwright
11/16/2021	$24.00 → $20.00	Outperform	SVB Leerink
8/17/2021	$26.00 → $24.00	Outperform	SVB Leerink